The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying cancer-screening company Grail without regulators’ approval, the latest setback for the deal.
Illumina announced a $7.1 billion acquisition of Grail in 2020, but the European Commission, the EU’s exec
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
